^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Published date:
10/15/2021
Excerpt:
In the HER2 exon 20G776>VC–mutant GEMM model, mobocertinib dosed at 30 mpk demonstrated a rapid tumor regression after just 2 weeks of treatment with close to complete response after 4 weeks of treatment...HER2 exon 20YVMA GEMM initially responded to mobocertinib but became acquired resistant upon continuous treatment...
DOI:
10.1158/0008-5472.CAN-21-1526